
Global Osteoarthritis Injectables Market Size study, by Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), by Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), by End-use, and Regional Forecasts 2022-2032
Description
The Global Osteoarthritis Injectables Market is valued approximately at USD 7.23 billion in 2023 and is anticipated to grow with a compound annual growth rate of more than 6.82% over the forecast period 2024–2032. As aging populations rise globally and the prevalence of joint-related disorders escalates, osteoarthritis has surfaced as a leading cause of disability and compromised quality of life. With an increasing number of patients turning away from invasive procedures, injectable therapies have garnered significant traction for offering targeted, non-surgical pain relief. These injectables, especially those based on corticosteroids and hyaluronic acid, are rapidly being adopted to alleviate joint inflammation and restore mobility—representing a crucial clinical tool in both acute flare-ups and long-term disease management.
The burgeoning demand is further fueled by the growing preference for minimally invasive interventions and outpatient settings. Hyaluronic acid injections, in particular, are gaining momentum due to their ability to restore the viscoelastic properties of synovial fluid, thereby enhancing joint lubrication and shock absorption. Meanwhile, corticosteroids are being employed to deliver potent anti-inflammatory effects, especially among patients with advanced degeneration. Innovations in formulation—such as extended-release injectables and novel delivery systems—are empowering physicians to tailor treatments based on anatomical sites, severity, and individual response, which in turn is fueling widespread clinical acceptance.
However, despite their growing popularity, the market encounters significant constraints. Concerns surrounding injection efficacy over time, adverse effects in long-term corticosteroid use, and inconsistent patient adherence due to repetitive injection schedules are curbing faster adoption. Furthermore, disparities in reimbursement policies and access to specialists—especially across developing nations—pose logistical and financial barriers to care. Nevertheless, opportunities abound in the form of pipeline product innovations, increased clinical trials assessing safety across patient subgroups, and strategic collaborations between device manufacturers and healthcare providers to broaden treatment access.
From an anatomical perspective, knee osteoarthritis remains the dominant contributor to injectable demand, primarily due to its higher incidence and the mechanical stress endured by the knee joint. Meanwhile, hip osteoarthritis is gradually catching up, driven by enhanced imaging techniques and early-stage diagnosis. The end-use landscape is transitioning as well—with hospitals and orthopedic clinics still leading—however, ambulatory surgical centers and specialty pain management centers are playing an increasingly pivotal role in delivering convenient and efficient care. Companies are strategically positioning their products across diverse end-user channels to maximize market penetration and establish brand preference.
Regionally, North America holds the lion’s share of the osteoarthritis injectables market, owing to its robust healthcare ecosystem, favorable reimbursement frameworks, and active engagement of leading manufacturers. Europe follows closely, with increased patient awareness and supportive regulatory pathways accelerating market growth. Meanwhile, Asia Pacific is poised for the fastest expansion through 2032. Factors such as rising geriatric populations, improving healthcare infrastructure, and growing demand for affordable, non-surgical treatments in countries like China, India, and Japan are expected to make this region a vital growth frontier in the coming years.
Major market player included in this report are:
• Bioventus Inc.
• Ferring Pharmaceuticals
• Zimmer Biomet Holdings, Inc.
• Seikagaku Corporation
• Anika Therapeutics, Inc.
• Sanofi S.A.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Fidia Farmaceutici S.p.A
• Mylan N.V.
• Chugai Pharmaceutical Co., Ltd.
• OrthogenRx Inc.
• Pfizer Inc.
• Novartis AG
• Flexion Therapeutics, Inc.
The detailed segments and sub-segment of the market are explained below:
By Injection Type
• Hyaluronic Acid Injections
• Corticosteroids Injections
By Anatomy
• Knee Osteoarthritis
• Hip Osteoarthritis
By End-use
• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
The burgeoning demand is further fueled by the growing preference for minimally invasive interventions and outpatient settings. Hyaluronic acid injections, in particular, are gaining momentum due to their ability to restore the viscoelastic properties of synovial fluid, thereby enhancing joint lubrication and shock absorption. Meanwhile, corticosteroids are being employed to deliver potent anti-inflammatory effects, especially among patients with advanced degeneration. Innovations in formulation—such as extended-release injectables and novel delivery systems—are empowering physicians to tailor treatments based on anatomical sites, severity, and individual response, which in turn is fueling widespread clinical acceptance.
However, despite their growing popularity, the market encounters significant constraints. Concerns surrounding injection efficacy over time, adverse effects in long-term corticosteroid use, and inconsistent patient adherence due to repetitive injection schedules are curbing faster adoption. Furthermore, disparities in reimbursement policies and access to specialists—especially across developing nations—pose logistical and financial barriers to care. Nevertheless, opportunities abound in the form of pipeline product innovations, increased clinical trials assessing safety across patient subgroups, and strategic collaborations between device manufacturers and healthcare providers to broaden treatment access.
From an anatomical perspective, knee osteoarthritis remains the dominant contributor to injectable demand, primarily due to its higher incidence and the mechanical stress endured by the knee joint. Meanwhile, hip osteoarthritis is gradually catching up, driven by enhanced imaging techniques and early-stage diagnosis. The end-use landscape is transitioning as well—with hospitals and orthopedic clinics still leading—however, ambulatory surgical centers and specialty pain management centers are playing an increasingly pivotal role in delivering convenient and efficient care. Companies are strategically positioning their products across diverse end-user channels to maximize market penetration and establish brand preference.
Regionally, North America holds the lion’s share of the osteoarthritis injectables market, owing to its robust healthcare ecosystem, favorable reimbursement frameworks, and active engagement of leading manufacturers. Europe follows closely, with increased patient awareness and supportive regulatory pathways accelerating market growth. Meanwhile, Asia Pacific is poised for the fastest expansion through 2032. Factors such as rising geriatric populations, improving healthcare infrastructure, and growing demand for affordable, non-surgical treatments in countries like China, India, and Japan are expected to make this region a vital growth frontier in the coming years.
Major market player included in this report are:
• Bioventus Inc.
• Ferring Pharmaceuticals
• Zimmer Biomet Holdings, Inc.
• Seikagaku Corporation
• Anika Therapeutics, Inc.
• Sanofi S.A.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Fidia Farmaceutici S.p.A
• Mylan N.V.
• Chugai Pharmaceutical Co., Ltd.
• OrthogenRx Inc.
• Pfizer Inc.
• Novartis AG
• Flexion Therapeutics, Inc.
The detailed segments and sub-segment of the market are explained below:
By Injection Type
• Hyaluronic Acid Injections
• Corticosteroids Injections
By Anatomy
• Knee Osteoarthritis
• Hip Osteoarthritis
By End-use
• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Table of Contents
285 Pages
- Chapter 1. Global Osteoarthritis Injectables Market Executive Summary
- 1.1. Global Osteoarthritis Injectables Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Injection Type
- 1.3.2. By Anatomy
- 1.3.3. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
- Chapter 2. Global Osteoarthritis Injectables Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Provider Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Reimbursement Frameworks
- 2.3.4.2. Physician Adoption Patterns
- 2.3.4.3. Patient Awareness & Acceptance
- 2.3.4.4. Outpatient Care Trends
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
- Chapter 3. Global Osteoarthritis Injectables Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Aging Population and Rising OA Prevalence
- 3.1.2. Shift Towards Minimally Invasive Therapies
- 3.1.3. Technological Innovations in Formulations
- 3.2. Market Challenges
- 3.2.1. Variable Efficacy and Repetitive Dosing
- 3.2.2. Long-term Safety Concerns of Corticosteroids
- 3.2.3. Reimbursement Disparities Across Regions
- 3.3. Market Opportunities
- 3.3.1. Extended-Release and Novel Delivery Platforms
- 3.3.2. Expansion in Ambulatory Surgical Centers
- 3.3.3. Pipeline Combination Therapies
- Chapter 4. Global Osteoarthritis Injectables Market Industry Analysis
- 4.1. Porter’s Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter’s Model
- 4.1.7. Impact Analysis of Five Forces
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
- Chapter 5. Global Osteoarthritis Injectables Market Size & Forecasts by Injection Type 2022–2032
- 5.1. Segment Dashboard
- 5.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Hyaluronic Acid Injections
- 5.2.2. Corticosteroids Injections
- Chapter 6. Global Osteoarthritis Injectables Market Size & Forecasts by Anatomy 2022–2032
- 6.1. Segment Dashboard
- 6.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Knee Osteoarthritis
- 6.2.2. Hip Osteoarthritis
- Chapter 7. Global Osteoarthritis Injectables Market Size & Forecasts by End-use 2022–2032
- 7.1. Segment Dashboard
- 7.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.2.1. Hospitals
- 7.2.2. Orthopedic Clinics
- 7.2.3. Ambulatory Surgical Centers
- 7.2.4. Others
- Chapter 8. Global Osteoarthritis Injectables Market Size & Forecasts by Region 2022–2032
- 8.1. North America Market
- 8.1.1. U.S. Market
- 8.1.1.1. Injection Type breakdown, 2022–2032
- 8.1.1.2. Anatomy breakdown, 2022–2032
- 8.1.2. Canada Market
- 8.2. Europe Market
- 8.2.1. UK Market
- 8.2.2. Germany Market
- 8.2.3. France Market
- 8.2.4. Spain Market
- 8.2.5. Italy Market
- 8.2.6. Rest of Europe Market
- 8.3. Asia Pacific Market
- 8.3.1. China Market
- 8.3.2. India Market
- 8.3.3. Japan Market
- 8.3.4. Australia Market
- 8.3.5. South Korea Market
- 8.3.6. Rest of Asia Pacific Market
- 8.4. Latin America Market
- 8.4.1. Brazil Market
- 8.4.2. Mexico Market
- 8.4.3. Rest of Latin America Market
- 8.5. Middle East & Africa Market
- 8.5.1. Saudi Arabia Market
- 8.5.2. South Africa Market
- 8.5.3. Rest of Middle East & Africa Market
- Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Bioventus Inc.
- 9.1.2. Ferring Pharmaceuticals
- 9.1.3. Zimmer Biomet Holdings, Inc.
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Bioventus Inc.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Ferring Pharmaceuticals
- 9.3.3. Zimmer Biomet Holdings, Inc.
- 9.3.4. Seikagaku Corporation
- 9.3.5. Anika Therapeutics, Inc.
- 9.3.6. Sanofi S.A.
- 9.3.7. Johnson & Johnson
- 9.3.8. Teva Pharmaceutical Industries Ltd.
- 9.3.9. Fidia Farmaceutici S.p.A
- 9.3.10. Mylan N.V.
- 9.3.11. Chugai Pharmaceutical Co., Ltd.
- 9.3.12. OrthogenRx Inc.
- 9.3.13. Pfizer Inc.
- 9.3.14. Novartis AG
- 9.3.15. Flexion Therapeutics, Inc.
- Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- List of Tables
- TABLE 1. Global Osteoarthritis Injectables market, report scope
- TABLE 2. Global market estimates & forecasts by Region 2022–2032 (USD Million)
- TABLE 3. Global market estimates & forecasts by Injection Type 2022–2032 (USD Million)
- TABLE 4. Global market estimates & forecasts by Anatomy 2022–2032 (USD Million)
- TABLE 5. Global market estimates & forecasts by End-use 2022–2032 (USD Million)
- TABLE 6. Global market by segment, estimates & forecasts, 2022–2032 (USD Million)
- TABLE 7. North America market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 8. Europe market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 9. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 10. Latin America market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 11. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 12. U.S. market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 13. Canada market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 14. UK market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 15. Germany market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 16. China market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 17. Brazil market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 18. Saudi Arabia market estimates & forecasts, 2022–2032 (USD Million)
- TABLE 19. Company market share analysis (2023)
- TABLE 20. Forecast methodology summary
- List of Figures
- FIGURE 1. Global Osteoarthritis Injectables market, research methodology
- FIGURE 2. Market estimation techniques
- FIGURE 3. Size estimates & forecast methods
- FIGURE 4. Key trends 2023
- FIGURE 5. Growth prospects 2022–2032
- FIGURE 6. Porter’s Five Forces model
- FIGURE 7. PESTEL analysis
- FIGURE 8. Value chain analysis
- FIGURE 9. By Injection Type, 2022 & 2032 (USD Million)
- FIGURE 10. By Anatomy, 2022 & 2032 (USD Million)
- FIGURE 11. By End-use, 2022 & 2032 (USD Million)
- FIGURE 12. Regional snapshot 2022 & 2032
- FIGURE 13. North America market 2022 & 2032 (USD Million)
- FIGURE 14. Europe market 2022 & 2032 (USD Million)
- FIGURE 15. Asia Pacific market 2022 & 2032 (USD Million)
- FIGURE 16. Latin America market 2022 & 2032 (USD Million)
- FIGURE 17. Middle East & Africa market 2022 & 2032 (USD Million)
- FIGURE 18. Competitive landscape heatmap
- FIGURE 19. Value-chain ecosystem
- FIGURE 20. Investment pockets by region
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.